Company: CMND
Filing Date: 2025-01-22
Form Type: 20-F
Source: 0001213900-25-005490
Chunk: 174

Company: Clearmind Medicine Inc.
Filing Date: 2025-01-22
Form: 20-F
Item: Item 5
Chunk 174
---
 material adverse effect on our
business, results of operations and financial condition. Our forecast of the period of time through which our financial resources will
be adequate to support our operations is a forward-looking statement that involves risks and uncertainties, and the actual amount of our
expenses could vary materially and adversely as a result of a number of factors. We have based our estimates on assumptions that may prove
to be wrong, and our expenses could prove to be significantly higher than we currently anticipate.

Our future capital requirements will depend on
many factors, including, but not limited to:

  the progress and costs of our research and development activities;  

  the costs of development and expansion of our operational infrastructure;  

  our ability, or that of our collaborators, to achieve development milestones and other events or developments under potential future licensing agreements;  

  the amount of revenues and contributions we receive under future licensing, collaboration, development and commercialization arrangements with respect to our technologies;  

  the costs of filing, prosecuting, enforcing and defending patent claims and other intellectual property rights;  

  the costs of contracting with third parties to provide sales and marketing capabilities for us or establishing such capabilities ourselves, once our technologies are developed and ready for com...  

  the costs of acquiring or undertaking development and commercialization efforts for any future products or technology;  

  the magnitude of our general and administrative expenses; and  

  any additional costs that we may incur under future in- and out-licensing arrangements relating to our technologies and futures products.  
 ─────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

Until we can generate significant recurring revenues,
we expect to satisfy our future cash needs through capital raising or by out-licensing and/or co-developing applications of one or more
of our product candidates. We cannot be certain that additional funding will be available to us on acceptable terms, if at all. If funds
are not available on favorable terms, or at all, we may be required to delay, reduce the scope of or eliminate research or development
efforts or plans for commercialization with respect to our technologies and make necessary change to our operations to reduce the level
of our expenditures in line with available resources.

We are a development-stage technology company and
it is not possible for us to predict with any degree of accuracy the outcome of our research and development efforts. As such, it is not
possible for us to predict with any degree of accuracy any significant trends, uncertainties, demands, commitments or events that